Analysts Are Bullish on These Healthcare Stocks: scPharmaceuticals Inc (SCPH), Lineage Cell Therapeutics, Inc. (LCTX)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on scPharmaceuticals Inc (SCPH) and Lineage Cell Therapeutics, Inc. (LCTX) with bullish sentiments.

scPharmaceuticals Inc (SCPH)

In a report released today, Douglas Tsao from H.C. Wainwright initiated coverage with a Buy rating on scPharmaceuticals Inc and a price target of $13.00. The company’s shares closed last Monday at $5.90.

According to TipRanks.com, Tsao is a 1-star analyst with an average return of -3.4% and a 44.5% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals Inc, Outlook Therapeutics Inc, and Protagonist Therapeutics.

scPharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $13.00.

See today’s analyst top recommended stocks >>

Lineage Cell Therapeutics, Inc. (LCTX)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Lineage Cell Therapeutics, Inc., with a price target of $4.00. The company’s shares closed last Monday at $0.93.

According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -12.3% and a 27.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lineage Cell Therapeutics, Inc. with a $3.50 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts